Form 4: Cardiff Oncology Director Mani Mohindru Granted New Stock Options

Cardiff Oncology, Inc. Director Mani Mohindru was granted 40,565 stock options with an exercise price of $3.16, exercisable from June 26, 2026, and expiring in 2035.

Summary

• Mani Mohindru, a Director of Cardiff Oncology, Inc., acquired 40,565 stock options.
• The options have an exercise price of $3.16 per share.
• These options become exercisable on June 26, 2026.
• The options are set to expire on June 26, 2035.
• Following this transaction, Mani Mohindru beneficially owns a total of 168,766 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's financial interests with the long-term performance of the company and shareholder value. It's a routine compensation event, so not exceptionally positive, but certainly not negative.

Positives

• The grant of 40,565 stock options to Director Mani Mohindru aligns management incentives with shareholder value creation, promoting long-term commitment to the company's success.

Future Outlook

The grant of stock options with a future exercisable date (June 26, 2026) and a long expiration period (June 26, 2035) indicates a long-term incentive structure for the director, aligning their interests with the company's future performance.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, like Cardiff Oncology, to attract, retain, and incentivize key personnel, aligning their compensation with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive and director compensation packages across the biotechnology sector, designed to align insider interests with long-term company growth and shareholder returns. The specific size and terms of the grant would typically be benchmarked against peer companies of similar market capitalization and development stage, though no specific comparisons are provided in this filing.

Related Party Transactions

• Grant of 40,565 stock options to Director Mani Mohindru with an exercise price of $3.16, exercisable from June 26, 2026, and expiring on June 26, 2035.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with shareholder value and long-term company performance.

Next Steps

• The granted stock options will become exercisable on June 26, 2026.

Key Dates

Keywords

Cardiff Oncology, CRDF, Stock Options, Insider Transaction, Form 4, Beneficial Ownership, Director, Equity Grant